Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral
February 26, 2024 9:04 AM EST
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has entered into a definitive Agreement and Plan of Merger (the Merger Agreement) under which Atlas Neon Parent, Inc. (Purchaser) and Atlas Neon Merger Sub, Inc. (Merger Sub) will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.... More
February 26, 2024 8:50 AM EST
NGM Biopharmaceuticals (NASDAQ: NGM) Halted, News Pending
...
More
